Hidden immunotherapy targets challenge dogma.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 21900591.
- Also identified by DOI 10.1126/scitranslmed.3002821 and PMC identifier 3426280.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In this issue of Science Translational Medicine, Guo et al. discuss the intriguing possibility that intracellular tumor antigen-specific monoclonal antibodies (mAbs) inhibit tumor growth and metastasis and prolong survival of tumor-bearing mice. Here, I discuss the implications of using intracellular targets in mAb-based immunotherapy as well as the possible underlying mechanisms of action.
Medical subject headings
- Antineoplastic Agents
- Cancer Vaccines
- Immunotherapy
- Neoplasms
- Oncogene Proteins
- Vaccination